Edition:
India

BioScrip Inc (BIOS.OQ)

BIOS.OQ on NASDAQ Stock Exchange Global Select Market

1.71USD
1:30am IST
Change (% chg)

$-0.01 (-0.58%)
Prev Close
$1.72
Open
$1.71
Day's High
$1.77
Day's Low
$1.68
Volume
270,955
Avg. Vol
311,700
52-wk High
$4.14
52-wk Low
$1.68

Latest Key Developments (Source: Significant Developments)

BioScrip Inc Reports Q3 Loss of $0.09 Per Share
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - BioScrip Inc ::BIOSCRIP REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 REVENUE $181 MILLION VERSUS I/B/E/S VIEW $171.1 MILLION.SEES FY 2018 REVENUE $710 MILLION TO $720 MILLION.QUARTERLY LOSS PER SHARE $0.09.SAYS MAINTAINING FY 2018 ADJUSTED EBITDA GUIDANCE BETWEEN $54 MILLION AND $58 MILLION.SAYS REMAIN INCREASINGLY CONFIDENT THAT BIOSCRIP CAN ACHIEVE AT LEAST $75 MILLION IN ADJUSTED EBITDA IN 2019.  Full Article

BioScrip Announces Additions To Senior Leadership Team
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - BioScrip Inc ::BIOSCRIP ANNOUNCES ADDITIONS TO SENIOR LEADERSHIP TEAM.BIOSCRIP - ‍ANNOUNCED APPOINTMENTS OF HARRIET BOOKER AS CHIEF OPERATING OFFICER, DANNY CLAYCOMB AS SENIOR VICE PRESIDENT, REVENUE CYCLE MANAGEMENT​.  Full Article

Bioscrip reports qtrly ‍loss per share $0.12​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Bioscrip Inc :Bioscrip reports third quarter 2017 financial results.Q3 revenue $198.7 million versus I/B/E/S view $200.9 million.Sees FY 2017 revenue $805 million to $810 million.Bioscrip Inc says ‍updated its adjusted EBITDA guidance to a range of $42.0 million to $44.0 million for full-year 2017​.Bioscrip Inc - Qtrly ‍loss per share $0.12​.Bioscrip Inc sees FY 2017 ‍loss per share in range of $0.58 to $0.64.FY2017 earnings per share view $-0.55, revenue view $824.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

BioScrip can now dispense & administer radicava treatment option for amyotrophic lateral sclerosis
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - Bioscrip Inc :BioScrip says can now dispense & administer Radicava (edaravone) treatment option for amyotrophic lateral sclerosis approved by U.S. FDA.  Full Article

Coliseum Capital reports 14.6 pct stake in Bioscrip
Friday, 8 Sep 2017 

Sept 8 (Reuters) - Bioscrip Inc :Coliseum Capital Management LLC reports 14.6 percent stake in Bioscrip Inc as of September 7, 2017 - SEC filing‍​.Coliseum Capital Management LLC earlier reported 16.5 percent stake in Bioscrip Inc as of August 17, 2017 - SEC filing‍​.  Full Article

U.S. files lawsuit against US Bioservices related to kickbacks, Novartis' Exjade
Tuesday, 22 Aug 2017 

Aug 22 (Reuters) - U.S. SAYS U.S. BIOSERVICES ARRANGED TO RECEIVE MORE PATIENT REFERRALS AND RELATED BENEFITS IN RETURN FOR ACHIEVING HIGHER PRESCRIPTION REFILL RATE FOR EXJADE:.  Full Article

BioScrip qtrly loss per share $0.26
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - BioScrip Inc :BioScrip reports second quarter 2017 financial results.Q2 revenue $218.1 million versus I/B/E/S view $220.2 million.Sees FY 2017 revenue $815 million to $835 million.Qtrly loss per share $0.26.Q2 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.BioScrip Inc - is reiterating its prior guidance of adjusted ebitda in range of $45.0 million to $55.0 million for full-year 2017..BioScrip Inc - company expects to incur restructuring expenses in a range of $11.0 million to $12.0 million in 2017.FY 2017 revenue view $865.9 million -- Thomson Reuters I/B/E/S.  Full Article

Ares Management reports 9.2 pct stake in Bioscrip
Monday, 10 Jul 2017 

July 10 (Reuters) - Ares Management::Ares Management reports 9.2 pct stake in Bioscrip as of June 29 - SEC filing.Ares Management says the shares of Bioscrip Inc were acquired, and are currently held, for investment purposes.Ares Management - pursuant to agreement, Ares shall have right to appoint one non-voting board observer for so long as Ares holds debt of co of at least $50 million.  Full Article

BioScrip announces new senior note facilities
Thursday, 29 Jun 2017 

June 29 (Reuters) - BioScrip Inc ::BioScrip announces new senior note facilities.BioScrip Inc - under agreement, company entered into a $200 million first lien note facility and a $110 million second lien note facility.BioScrip Inc - to use proceeds of facilities to repay in full all amounts outstanding under its previous senior credit facilities and its priming credit agreement.BioScrip Inc - also as part of agreement, will receive a $16 million common stock investment, and will issue common stock warrants with a 10-year term..  Full Article

Bioscrip provides update on Unitedhealthcare contract
Tuesday, 30 May 2017 

May 30 (Reuters) - Bioscrip Inc :Bioscrip provides update on Unitedhealthcare contract.Bioscrip Inc - ‍reached an agreement to continue to provide certain core product lines to unitedhealthcare beyond September 30, 2017​.Bioscrip Inc says company is reiterating its prior guidance for adjusted EBITDA in range of $45.0 million to $55.0 million for full-year 2017.Bioscrip Inc - ‍with agreement, Bioscrip will retain approximately $35 million of annualized profitable core revenue​.  Full Article